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Retreatment with anti-EGFR based
therapies in metastatic colorectal cancer:
impact of intervening time interval and
prior anti-EGFR response
X. Liu1, G. C. George1, A. M. Tsimberidou1, A. Naing1, J. J. Wheler1, S. Kopetz2, S. Fu1, S. A. Piha-Paul1, C. Eng2,
G. S. Falchook1, F. Janku1, C. Garrett2, D. Karp1, R. Kurzrock3, R. Zinner1, K. Raghav2, V. Subbiah1, K. Hess4,
F. Meric-Bernstam1, D. S. Hong1*† and M. J. Overman2*†
Abstract
Background: This retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in
order to explore the concept of clonal evolution by evaluating the impact of prior activity and intervening time interval.
Methods: Eighty-nine KRAS exon 2-wild-type metastatic colorectal patients were retreated on phase I/II clinical trials
containing anti-EGFR therapies after progressing on prior cetuximab or panitumumab. Response on prior anti-EGFR therapy
was defined retrospectively per physician-records as response or stable disease ≥6 months. Multivariable statistical methods
included a multiple logistic regression model for response, and Cox proportional hazards model for progression-free survival.
Results: Retreatment anti-EGFR agents were cetuximab (n = 76) or cetuximab plus erlotinib (n = 13). The median interval
time between prior and retreatment regimens was 4.57 months (range: 0.46-58.7). Patients who responded to the prior
cetuximab or panitumumab were more likely to obtain clinical benefit to the retreatment compared to the non-responders
in both univariate (p = 0.007) and multivariate analyses (OR: 3.38, 95 % CI: 1.27, 9.31, p = 0.019). The clinical benefit rate on
retreatment also showed a marginally significant association with interval time between the two anti-EGFR based therapies
(p = 0.053). Median progression-free survival on retreatment was increased in prior responders (4.9 months, 95 % CI: 3.6, 6.2)
compared to prior non-responders (2.5 months, 95 % CI, 1.58, 3.42) in univariate (p = 0.064) and multivariate analysis (HR:
0.70, 95 % CI: 0.43-1.15, p = 0.156).
Conclusion: Our data lends support to the concept of clonal evolution, though the clinical impact appears less robust than
previously reported. Further work to determine which patients benefit from retreatment post progression is needed.
Keywords: Retreatment, Anti-EGFR treatment, KRAS-wt CRC
Background
Colorectal cancer (CRC) is one of the most common can-
cers worldwide. Systemic therapy is the mainstay of man-
agement for patients with metastatic CRC, involving the
use of active cytotoxic drugs and biological agents either in
combination or as single agents. Two antibodies targeting
the epidermal growth factor receptor (EGFR), cetuximab
and panitumumab, have been approved for the treatment
of metastatic CRC. Activating mutations downstream to
EGFR, especially in the RAS superfamily of oncoproteins
(i.e. NRAS, KRAS) have been correlated with lack of
response to anti-EGFR therapy. In 2009, the FDA restricted
the use of cetuximab and panitumumab to patients lacking
mutations in exon 2 (codons 12 + 13) of KRAS [1, 2].
Recently, mutations in KRAS have been detected in
circulating tumor DNA in colorectal cancer patients
with KRAS-wildtype (wt) cancers who had progressed
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on anti-EGFR therapy. Mathematical modeling of such
resistance suggested that subclones harboring the KRAS
mutations were present in low frequency in the tumor be-
fore treatment [3]. This finding supports the theory that
the mechanism of resistance to anti-EGFR agents may be
from intratumor heterogeneity and clonal evolution via
drug-selection [4]. Based upon this theory a treatment
break after developing acquired anti-EGFR resistance may
allow the dominant clone that is KRAS-wt to repopulate
and render a tumor sensitive to anti-EGFR therapy.
Success with a retreatment strategy utilizing targeted
therapy has been reported with other agents in different
types of cancer, such as trastuzumab in breast cancer [5]
and sunitinib in gastrointestinal stromal tumor [6]. Re-
cent small studies have suggested a benefit from a
retreatment strategy in colorectal cancer with the use of
anti-EGFR therapy [7–9]. In a phase II study by Santini
et al. 39 patients with KRAS exon 2-wt metastatic CRC
who had previously progressed following an initial clin-
ical benefit to cetuximab-based therapy, were retreated
with cetuximab and irinotecan. Results demonstrated an
overall response rate of 53.8 %, stable disease rate was
35.9 %, and the median progression-free survival was
6.6 months [8]. Metges et al. (PANERB trial) prospect-
ively treated 32 KRAS wild-type metastatic CRC patients
with cetuximab and irinotecan followed by panitumu-
mab monotherapy after progression. In 11 patients who
had previously responded to cetuximab and irinotecan,
an objective response rate of 22 % to panitumumab, in-
cluding a disease control rate (objective response plus
stable disease) of 73 % was observed [10]. In heavily pre-
treated patients without acquired resistance to prior
cetuximab-based regimens, panitumumab obtained 67 %
disease control rate and 30 % objective response rate, with
median PFS of 4.2 and median OS of 9.6 months [11].
In this study, we reviewed 89 patients with advanced
KRAS exon 2-wt CRC who had progressed on anti-EGFR
therapy and were subsequently retreated on an anti-EGFR
containing phase I/II clinical trial. Our goal was to evalu-
ate the impact of both prior anti-EGFR response and
interval length from prior anti-EGFR therapy upon the
outcome of patients retreated with anti-EGFR therapy.
Methods
Patient selection
Patients with KRAS exon 2 (codons 12 + 13)-wt CRC
who had progressed on their previous anti-EGFR-based
therapy (cetuximab or panitumumab) and subsequently
received at least two doses of an anti-EGFR monoclonal
antibody in the context of a phase I or phase I/II clinical
trial at MD Anderson Cancer Center were eligible for
analysis on or before 2/27/2013. Progression on prior
anti-EGFR based therapy prior to retreatment clinical
trial was based upon retrospective review of the medical
records. As this was a retrospective study informed con-
sent was waived by the MD Anderson Cancer Center
Institutional Review Board.
Tissue samples and mutation analyses
All histology was centrally reviewed at MD Anderson. All
tissue samples were obtained and molecularly tested as
part of standard of care. Mutational results for KRAS exon
2 (codons 12 and 13) and when available extended KRAS,
NRAS, BRAF V600E, and PIK3CA were recorded from
standard of care mutational results done in accordance
with the Clinical Laboratory Improvement Amendment
(CLIA)-certified Molecular Diagnostic Laboratory within
the Division of Pathology and Laboratory Medicine at MD
Anderson. DNA was extracted from macro-dissected,
paraffinembedded tumor sections and over the time
period studied three testing methodologies were utilized.
In 85 cases PCR-based DNA sequencing for KRAS codons
12 and 13 [exon 2] with and without codon 61 [exon 3]
and 146 [exon 4] was used. In 8 cases a MassARRAY plat-
form [12] for hotspots in 11 cancer genes including KRAS
codons 12 + 13 [exon 2], 61 [exon 3], and146 [exon 4],
NRAS codons 12 + 13 [exon 2] and 146 [exon 4], BRAF
V600E, and PIK3CA exon 9 and 20 hotspots was used. In
5 cases an Ampli-Seq 46 gene cancer panel using Ion Tor-
rent PGM Sequencer [13] (Life Technologies, CA) includ-
ing KRAS codons 12 + 13 + 19 + 22 [exon 2], 61 [exon 3],
146 [exon 4], and NRAS codons 12 + 13 + 18 [exon 2] and
61 [exon 3], BRAF V600E, and PIK3CA exon 9 and 20
hotspots was used. The lower limit of detection is 10 %
for the first two methodologies and 5 % for the third. In a
subset of cases additional PCR-based DNA sequencing
was conducted for BRAF V600E (n = 54), NRAS (n = 12),
and PIK3CA (n = 24).
Data collection
Clinical information included age, race, the date of
initial diagnosis and staging, KRAS, NRAS, BRAF, and
PIK3CA mutational status of the tumor specimen, prior
treatment history, baseline Eastern Cooperative Oncology
Group (ECOG) performance status (PS), serum albumin,
serum lactate dehydrogenase (LDH), and number of
tumor metastatic sites were collected at the initiation of
anti-EGFR retreatment. Two individual reviewers worked
independently on reviewing patient electronic medical
records and crosschecking the collected data.
For patients treated on more than one anti-EGFR-based
regimen before retreatment (n = 18), data from the last
anti-EGFR-based therapy were used for analysis. Response
prior to the retreatment clinical trial was defined as a
radiographic response or stable disease ≥6 months deter-
mined by the treating physician’s records. Responses on
the retreatment clinical trial were prospectively deter-
mined for each clinical trial and categorized per RECIST
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1.0 [14] or 1.1 [15] criteria. Clinical benefit on anti-EGFR
retreatment clinical trial was defined as complete response
(CR), partial response (PR), or stable disease (SD).
Progression-free survival (PFS) was calculated as the time
from the start of therapy to the first observation of disease
progression or death, whichever occurred first. Patients
without progression were censored on February 27, 2013.
Statistical analysis
Univariable analyses for clinical benefit/response and
PFS included chi-square and log-rank tests, respectively.
Multivariable analyses for response and PFS utilized a
multiple logistic regression and a Cox proportional haz-
ards model, respectively. Covariates included in the mul-
tivariable models were response on prior anti-EGFR
treatment, interval between conclusion of previous anti-
EGFR treatment and initiation of anti-EGFR retreat-
ment, age, race, gender, PS, and Royal Marsden Hospital
(RMH) prognostic score comprising points for serum
LDH and albumin levels, and number of metastatic sites
[16]. The variables that were included in the multivari-
able model in the present study have been included in
multivariable models in previous studies of phase 1 clin-
ical trials [17, 18]. All of these variables were included in
the multivariable model so as to avoid confounding bias
that could potentially result from exclusion of specific
variables [19]. All statistical analyses were carried out
using SPSS 19 (SPSS Chicago, IL) by our biostatisticians
GG and KH.
Results
Patient and treatment characteristics
We identified 97 KRAS exon 2-wt CRC patients who
were treated on a phase I or phase I/II clinical trials con-
taining anti-EGFR therapy and had progressed on prior
cetuximab- or panitumumab-containing regimens from
5/2007 to 12/2012. An additional 8 patients (4 with
NRAS mutations and 4 with BRAF V600E mutations)
were excluded. The final analyzed dataset consisted of
89 patients, who were predominantly Caucasian (71 %),
younger age (<60 years old, 64 %), and evenly distributed
in gender, Table 1. At the initiation of the anti-EGFR re-
challenge, they had good PS (ECOG < = 1, 94 %), normal
albumin levels (81 %) and elevated LDH levels (79 %).
Prior anti-EGFR therapy was combined with chemo-
therapy in 90 % (80/89) and consisted of single agent
anti-EGFR therapy in 9 % (8/89). Anti-EGFR therapy on
the retreatment clinical trials utilized cetuximab in all
cases. In the retreatment clinical trials, cetuximab was
combined with chemotherapy and a targeted therapy in
73 % (65/89) and with a targeted therapy alone in 27 %
(24/89), Table 2. Prior response, defined as response or
stable disease ≥6 months, was seen in 41.6 % (37/89) of
patients on prior anti-EGFR-based therapies. The median
interval time between prior and retreatment anti-EGFR-
based therapy was 4.6 months (range: 0.46-58.7). No add-
itional RAS pathway mutations were identified in the 70
patients tested for KRAS exons 3 or 4, or for the 23 pa-
tients tested for NRAS. A BRAF V600E mutation was
Table 1 Patients’ demographic and baseline clinical
characteristics (n = 89)
Characteristic Count (%)
Gender, n (%)
Male 45 (49)
Female 44 (51)
Age, n (%)
< 60 years 57 (64)
≥ 60 years 32 (36)
Race, n (%)
Non-Hispanic White 63 (71)
African-American 18 (20)
Hispanic 8 (9)
Performance status, n (%)
0 35 (39)
1 49 (55)
2 5 (6)
Histological grade
Well 3 (3)
Moderate 69 (78)
Poor 17 (19)
Number of metastatic sites
< 3 42 (47)
≥ 3 47 (53)
Serum albumin
Normal 72 (81)
Low (<3.5 g/dL) 17 (19)
Serum LDH
Normal 19 (21)
Elevated (>618 IU/L) 70 (79)
RMH Score
< 2 43 (48)
≥ 2 46 (52)
KRAS exon 2 wild-typea 89 (100)
KRAS non-exon 2 mutations (n = 70) 0
NRAS mutations (n = 23) 0
BRAF V600E mutation (n = 64) 0
PIK3CA mutations (n = 37) 6
aKRAS exon 2 wild-type status included codons 12 and 13 (exon 2); non-exon
2 KRAS mutations included exon 3 in 55 cases and exon 3 + 4 in 15 cases;
NRAS mutations included exons 2 in 23, exon 3 in 17 and exon 4 in 6; PIK3CA
mutations included hotspots within exons 9 and 20
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absent in the 64 tested patients and a PI3KCA mutation
was identified in 6 of 37 tested patients.
Improved clinical benefit to cetuximab-based clinical trial
retreatment in prior responders
Of the 86 patients with response information on the
cetuximab-based retreatments, a clinical benefit, de-
fined as a CR, PR, or SD, occurred in 58 % (50/86)
of patients. Of the 13 patients who were treated with
cetuximab and erlotinib, 1 had a PR, 4 SD, and 8 PD
as best response. In univariate analyses, patients who
responded to the prior anti-EGFR-based regimens were
more likely to obtain a clinical benefit to cetuximab-
based retreatment compared to the prior non-responders
(p = 0.007), Table 3. In addition, a trend was noted where
patients with longer (≥ median) interval length between
prior and retreatment anti-EGFR therapy were more likely
to respond to cetuximab-based retreatment compared
with patients with shorter interval length (< median),
p = 0.053. Other factors such as race (p = 0.14), age
(p = 0.99), serum albumin (p = 0.95), LDH (p = 0.28),
RMH prognostic score (p = 1.0), PS (p = 0.53) or number
of metastatic sites (p = 0.49), were not statistically associ-
ated with obtaining a response to cetuximab-based
retreatment, Table 3. In addition, patients were signifi-
cantly more likely to respond to cetuximab-based retreat-
ment if they were prior responders to anti-EGFR therapy
and were retreated after a longer interval than prior
non-responders after either a longer (p = 0.032) or a
shorter interval, p = 0.003, Fig. 1.
A multiple logistic regression model confirmed that
response on prior anti-EGFR therapy was a significant
predictor for clinical benefit on anti-EGFR retreatment
(OR: 3.38, 95 % CI: 1.27, 9.31, p = 0.019), Table 4. Des-
pite the lack of statistical significance for the interaction
of treatment response and interval length in the multi-
variate model, the markedly increased odds ratio for the
combination of long interval length and prior treatment
response (OR 6.7) in comparison to either long interval
(OR 1.6) or prior treatment response alone (OR 2.3) sug-
gests that such an interaction may exist but that we had
insufficient data to detect it as statistically significant,
Additional file 1: Table S1.
PFS on cetuximab-based clinical trial retreatment were
marginally increased in prior-responders
Median PFS on cetuximab-based retreatment was
4.9 months (95 % CI: 3.59, 6.20) in prior responders
compared to 2.5 months (95 % CI, 1.58, 3.42) in prior
non-responders, p = 0.064, Fig. 2. No statistically sig-
nificant differences with regard to PFS were seen for
the other variables, such as interval length between
prior anti-EGFR-based therapy and cetuximab retreat-
ment (p = 0.29), age (p = 0.62), number of metastatic
sites (p = 0.07), serum albumin levels (p = 0.92), serum
LDH levels (p = 0.67), RMH prognostic score (p = 0.41) or
PS (p = 0.29) at the initiation of retreatment, Table 3. The
multivariable Cox proportional hazards model revealed no
significant difference in PFS on cetuximab retreatment ac-
cording to prior anti-EGFR response (HR: 0.70, 95 % CI:
0.43-1.15, p = 0.156), interval length between prior anti-
EGFR-based therapy and cetuximab retreatment (HR:
0.72, 95 % CI: 0.45-1.16, p = 0.177), or other demographic
or clinical variables, Table 4.
Discussion
This study shows anti-tumor activity with anti-EGFR
retreatment in KRAS exon 2-wt CRC patients who had
progressed on prior cetuximab- or panitumumab-based
treatment. Prior responders were more likely to achieve
Table 2 Characteristics related to prior and retreatment anti-EGFR
regimens
Characteristic N/total # pts (%)
Response on prior anti-EGFR therapy
Response or stable disease ≥6 m 37/89 (42)
No response or stable disease <6 m 52/89 (58)
Clinical benefit on anti-EGFR retreatment
Best response CR/PR/SD 50/86 (58)
Best response PD 36/86 (42)
Prior anti-EGFR-based regimens
Panitumumab monotherapy 6/89 (7)
Panitumumab + Chemotherapya 9/89 (10)
Panitumumab and AMG-102/AMG-479 1/89 (1)
Cetuximab monotherapy 2/89 (2)
Cetuximab + Chemotherapyb 71/89 (80)
Anti-EGFR-based retreatment regimens
Cetuximab, FOLFOX, and dasatinib 31/89 (35)
Cetuximab, irinotecan, and bevacizumab 12/89 (13)
Cetuximab and erlotinib 13/89 (15)
Cetuximab and sirolimus 11/89 (12)
Cetuximab, HAIc oxaliplatin, 5-FU, bevacizumab 20/89 (23)
Cetuximab, HAI oxaliplatin, and bevacizumab 2/89 (2)
Interval length between prior and retreatment
anti-EGFR therapies
Months
Median 4.57
Mean ± Standard Deviation 7.34 ± 8.9
Range 0.46 – 58.7
aChemotherapy regimen: irinotecan (7), FOLFIRI (1), 5-FU and irinotecan (1)
bChemotherapy regimen: Irinotecan (42), FOLFIRI (15), FOLFOX (5), irinotecan
and arq197 (3), irinotecan and apomab (1), irinotecan and bevacizumab (3),
FOLFOX and dasatinib (1), Xelox (1)
cHAI = Hepatic Arterial Infusion
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a clinical benefit on the cetuximab containing retreat-
ment clinical trial. In addition a longer interval length
between prior and retreatment anti-EGFR therapy dem-
onstrated a non-significant trend favoring an increased
likelihood of obtaining a clinical benefit from anti-EGFR
retreatment. This study lends support to the notion of
anti-EGFR retreatment in metastatic CRC, however the
magnitude of benefit from retreatment appears less than
previously reported [8, 9].
In the phase II prospective study by Santini et al.,
cetuximab retreatment resulted in an overall response
rate of 53.8 %, stable disease rate was 35.9 %, and the
median progression-free survival was 6.6 months [8].
The median interval time between therapies was 6 months
whereas in our study it was 4.6 months. Similar to Santini
et al. a response to prior anti-EGFR therapy was defined
as a response or stable disease lasting ≥ 6 months, how-
ever our definition was based upon clinical reports and
not RECIST. Another phase II prospective study by Fora
et al. reported benefit from EGFR retreatment with a
higher dose of cetuximab (500 mg/m2 weekly) in combin-
ation with irinotecan in 20 KRAS-wt metastatic CRC pa-
tients who had previously progressed on both agents [9].
A clinical benefit was seen in 9 patients (1 PR and 8 SD)
and in an exploratory analysis patients treated >2 months
from prior cetuximab progression had an improved PFS,
p = 0.02). In the PANERB trial that prospectively treated
32 KRAS wild-type metastatic CRC patients with
Table 3 Univariate associations between clinical benefit and PFS on anti-EGFR-based clinical trial retreatment
Patient characteristics Clinical benefit PFS
Total (n) Responded n (%) p Total (n) Progressed (n) Median (95 % CI) p
Response to prior anti-EGFR treatment
No 50 23 (46) 0.007 52 45 2.50 (1.58, 3.42) 0.064
Yes 36 27 (75) 37 31 4.90 (3.60, 6.20)
Interval length between treatments
< median 42 20 (48) 0.053 44 40 3.20 (1.97, 4.43) 0.286
≥ median 44 30 (68) 45 36 4.10 (2.61, 5.59)
Race/Ethnicity
Non-White 24 17(71) 0.138 26 22 5.20 (3.94, 6.46) 0.034
White 62 33(53) 63 54 3.00 (1.92, 4.08)
Gender
Female 43 24 (56) 0.662 44 41 3.80 (2.88, 4.72) 0.323
Male 43 26 (61) 45 35 3.70 (2.48, 4.92)
Age
< 60 years 55 32 (58) 0.992 57 50 3.70 (2.91, 4.49) 0.619
≥ 60 years 31 18 (58) 32 26 3.80 (2.03, 5.57)
PS (ECOG)
0 32 20 (63) 0.528 35 28 3.80 (2.67, 4.93) 0.286
≥ 1 54 30 (56) 54 48 3.60 (2.08, 5.12)
Number of metastatic sites
< 3 42 26 (62) 0.489 42 35 4.50 (3.03, 5.97) 0.077
≥ 3 44 24 (55) 47 41 3.20 (1.92, 4.48)
Serum albumin
Normal 69 40 (58) 0.949 72 61 3.80 (3.18, 4.42) 0.920
Low 17 10 (59) 17 15 3.00 (0.00, 6.77)
Serum LDH
Normal 19 9 (47) 0.281 19 15 2.80 (0.37, 5.24) 0.667
Elevated 67 41(61) 70 61 3.80 (3.05, 4.55)
RMH score
0 or 1 43 25 (58) 1.000 43 35 3.70 (2.00, 5.40) 0.408
2 or 3 43 25 (58) 46 41 3.80 (2.81, 4.79)
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cetuximab and irinotecan followed by panitumumab
monotherapy after progression, an objective response rate
of 22 % to panitumumab, including a disease control rate
(objective response plus stable disease) of 73 % was ob-
served in 11 patients who had previously responded to
cetuximab and irinotecan [10].
Recent data has demonstrated that mutations in NRAS
exons 2, 3 and 4, and KRAS exon 3 and 4, termed ex-
tended RAS testing, confer resistance to anti-EGFR ther-
apy in metastatic CRC. [20–22] A recent meta-analysis
has estimated the prevalence of KRAS exon 3 and 4 mu-
tations to be 11 %, and NRAS mutations to be 9.1 %
[23]. It has also been reported that a more sensitive
technology may detect additional mutations that confer
resistance to anti-EGFR therapies [24]. A fundamental
limitation of this report is that due to the use of stand-
ard of care testing, we were not able to exclude all pa-
tients with innate anti-EGFR resistance due to extended
RAS mutations, as testing was done for non-exon 2
KRAS mutations in 70 patients, 79 %, and for NRAS
mutations in 23 patients, 26 %.
A number of recent reports utilizing circulating free
DNA have correlated the occurrence of EGFR resistance
with the acquirement of mutations in both KRAS and
NRAS, as well as other acquired alterations such as
EGFR mutation or MET amplification [3, 25, 26]. In
Fig. 1 Prior responders with longer interval length were more likely to respond to anti-EGFR retreatment. Prior responders with longer interval length
(longer intervening time between prior anti-EGFR therapy and anti-EGFR retreatment) were more likely to respond to anti-EGFR retreatment by analysis
combining prior response to anti-EGFR retreatment and intervening time interval between anti-EGFR treatments: short (< median) or long (≥ median)
Table 4 Multivariate models for clinical benefit and PFS on anti-EGFR-based clinical trial retreatment
Characteristic Clinical Benefit PFS
OR 95 % CI pa HR 95 % CI pb
Responded on prior anti-EGFR treatments, yes vs. no 3.38 (1.27, 9.31) 0.019 0.70 (0.43, 1.15) 0.156
Interval length, ≥ median vs. < median 2.37 (0.89, 6.31) 0.086 0.72 (0.45, 1.16) 0.177
Race, White vs. non-White 0.41 (0.13, 1.25) 0.116 1.75 (1.02, 3.01) 0.043
Age, ≥ 60 years vs. < 60 years 0.70 (0.25, 1.96) 0.500 1.10 (0.65, 1.87) 0.718
Gender, male vs. female 1.28 (0.50, 3.25) 0.611 0.78 (0.49, 1.24) 0.295
RMH Score, ≥ 2 vs. < 2 0.79 (0.29, 2.11) 0.633 1.32 (0.81, 2.16) 0.273
PS by ECOG, ≥ 1 versus < 1 0.76 (0.28, 2.10) 0.597 1.25 (0.76, 2.05) 0.381
aBased on a multivariable logistic regression model
bBased on a multivariable Cox proportional hazards model
OR Odds Ratio, HR Hazard Ratio
Multivariable models were tested for a possible interaction between response on prior anti-EGFR therapy vs. non-response on prior therapy (1, 0) and interval
length at or above the median vs. below the median (1, 0). The interaction term between response on prior anti-EGFR therapy vs. non-response on prior therapy
(1, 0) and interval length at or above the median vs. below the median (1, 0) was not significant in either model. Thus, the interaction term was not included in
the final multivariable models
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addition, the exact threshold for determining RAS muta-
tional status is uncertain with data from the CRYSTAL
study suggesting improved discrimination with a muta-
tion threshold down to 5 % [27]. Within this report we
are unable to address these various resistance mecha-
nisms retrospectively as both tumor tissue and blood
were inconsistently collected across the various clinical
trials studied. However, these recent findings regarding
acquired resistance mechanisms to anti-EGFR therapy
provide clear insights into future studies to help refine
and better predict which patients are truly benefiting
from an anti-EGFR retreatment strategy.
This study lends supports to the concept of intratumor
heterogeneity and clonal evolution via drug selection as
a mechanism of resistance to anti-EGFR agents. Clonal
evolution generated by genetic instability and genetic
drift is not a new concept [28]. Evidence of intratumor
heterogeneity and branched evolutionary growth has been
revealed in solid tumors via both tissue sections and multi-
region sequencing [29–32]. Kreso et al., followed the re-
population dynamics of 150 single lentivirus-marked
lineages from ten human CRCs through serial xenograft
passages in mice using DNA copy number profiling, se-
quencing and lentiviral lineage tracking. This study showed
that individual tumor cells within a uniform genetic
lineage remained stable on serial transplantation, but were
functionally heterogeneous with variable chemotherapy
tolerance [33]. In metastatic CRC Morelli et al. analyzed
circulating cell free DNA and tissue samples collected
from EGFR refractory patients and demonstrated that the
percent of acquired KRAS mutant alleles detected in
plasma declined with greater time away from anti-EGFR
therapy [26]. Repopulation of sensitive subclones after the
cessation of treatment has been noted in a number of
model systems [34, 35]. Retreatment has demonstrated ef-
ficacy in multiple types of tumors in clinical trials [34, 36].
In non-small cell lung cancer cell lines, evolutionary
mathematical modeling of tumor behavior demonstrated
that optimally timed sequential strategies yielded large
improvements in survival outcome with anti-EGFR
treatment [37, 38].
Our study is limited by the use of heterogenous anti-
EGFR retreatments. Effects of the combined regimens
may obscure the differential effectiveness of the anti-
EGFR retreatment. Due to the heterogeneity of included
clinical trials and the sample size, the impact of each in-
dividual re-treatment regiment could not be determined.
Although all anti-EGFR retreatment efficacy assessments
were conducted on prospective clinical trials, the evalua-
tions of prior anti-EGFR therapies were based on retro-
spective review, and due to the inability to review these
scans response criteria were not based upon RECIST. In
addition, the dose escalation of these phase 1 studies
precluded a small subset of patients from receiving the
P = 0.064 by log-rank test
Fig. 2 PFS on cetuximab-based retreatments by response on prior anti-EGFR-based therapies. Median PFS on the anti-EGFR-based retreatments
was 4.90 months (95 % CI: 3.59, 6.20) in prior responders compared to that of 2.5 months (95 % CI, 1.58, 3.42) in prior non-responders (p = 0.064)
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full dose of cetuximab. As this study utilized standard of
care mutation testing the majority of patients in this
study did not have extended RAS testing of NRAS and
non-exon 2 KRAS. In addition highly sensitive muta-
tional testing methodology were not utilized in these pa-
tients and thus the impact of low frequency RAS
mutations could not be determined [24]. Thus, our re-
sults may be confounded by the presence of a small subset
of patients with innate anti-EGFR resistance from pre-
existing mutations. Despite these limitations, this study
represents the largest metastatic CRC anti-EGFR retreat-
ment population published, and has attempted to evaluate
both prior EGFR response and duration from prior ther-
apy in contributing to anti-EGFR retreatment efficacy.
Conclusions
In conclusion, this study supports the further explor-
ation of anti-EGFR retreatment in metastatic CRC, which
is ongoing with both the CRICKET (NCT02296203) and
REGAIN (NCT02316496) phase II clinical trials investi-
gating retreatment with cetuximab following prior anti-
EGFR progression. Understanding the mechanisms of
acquired resistance to anti-EGFR therapy in CRC will en-
able the improved identification of patients who are likely
to benefit from a retreatment approach. However, at the
present time, rechallenge with an anti-EGFR therapy
remains investigational and should be conducted in the
context of a clinical trial.
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